title: Renal cell carcinoma detection and systemic therapy with tumour-affine gallium-67 and with yttrium-90 citrate solutions.
abstract: BACKGROUND
  There have been no major advances in the systemic detection of renal cell carcinoma (RCC) and its unpredictable metastases. Surgery, thus, remains the mainstay of the curative treatment for the localized disease. The propose of the present study has been to systemically detect and treat advanced RCC respectively with Ga-67 and Y-90 radiopharmaceuticals containing tumour-affine species.
  
  
  METHODS
  Thirty-three RCC patients were imaged with Tc-99m-MDP and then with Ga-67 citrate solution in order to detect RCC and its metastases. Yttrium-90 citrate solution, containing the radionuclide species chromatographically and electrophoretically identical to those in RCC-affine Ga-67 solution, was administered i.v. for systemic therapy of advanced RCC. Total-body distribution of Y-90 was studied with a gamma-camera equipped with an ultra-high-sensitivity collimator. The efficacy of the therapy was studied by the clinical condition of the patient and by the total-body scintigraphic imaging with Tc-99m-MDP and with Ga-67 citrate solution.
  
  
  RESULTS
  Ga-67 detects RCC bone metastases better than Tc-99m-MDP. Systemic therapy of RCC metastasized to bones, lung and brain was obtained with RCC-affine Y-90 citrate solution.
  
  
  CONCLUSIONS
  Third group metal radionuclides, Ga-67 and Y-90, detect and treat advanced RCC.
authors.affiliation: Servizio di Medicina Nucleare, Ospedale S. Eugenio, Roma, Italy.
authors.forename: S K
authors.initials: SK
authors.lastname: Shukla
authors.forename: G S
authors.initials: GS
authors.lastname: Limouris
authors.forename: R
authors.initials: R
authors.lastname: Cusumano
authors.forename: A
authors.initials: A
authors.lastname: Acconcia
authors.forename: C
authors.initials: C
authors.lastname: Cipriani
authors.forename: G
authors.initials: G
authors.lastname: Argiro
authors.forename: G
authors.initials: G
authors.lastname: Atzei
authors.forename: S
authors.initials: S
authors.lastname: Boemi
mesh_terms: D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy / Q000556:secondary; D002292:Carcinoma, Renal Cell / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy*; D002951:Citrates / Q000627:therapeutic use*; D005260:Female; D005710:Gallium Radioisotopes / Q000627:therapeutic use*; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009942:Organometallic Compounds / Q000627:therapeutic use*; D013669:Technetium Tc 99m Medronate; D014055:Tomography, Emission-Computed; D015021:Yttrium Radioisotopes / Q000627:therapeutic use*
chemical_list: D002951:Citrates; D005710:Gallium Radioisotopes; D009942:Organometallic Compounds; D015021:Yttrium Radioisotopes; C045937:yttrium citrate; D013669:Technetium Tc 99m Medronate